SCHEMBL2983642

SCHEMBL2983642

CC(=O)Nc1ccc(C(C)=O)c(F)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.60
SMN1; SMN2 Q16637 4/20 0.56
NPC1 O15118 5/20 0.55
RAB9A P51151 4/20 0.52
CASP3 P42574 1/20 0.51
SENP8 Q96LD8 1/20 0.51
SENP7 Q9BQF6 1/20 0.51
SENP6 Q9GZR1 1/20 0.51
PREP P48147 1/20 0.51
POLB P06746 2/20 0.50
HTT P42858 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
MAPT P10636 2/20 0.47
KDM4E B2RXH2 1/20 0.47
GLA P06280 1/20 0.47
TNNI3 P19429 1/20 0.47
TNNT2 P45379 1/20 0.47
TNNC1 P63316 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1966151 0.87 HDAC1 (0.58) HDAC1SMN1; SMN2NPC1RAB9ACASP3
SCHEMBL18152960 0.87 HDAC1 (0.48) HDAC1SMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL2925453 0.86 HDAC1 (0.61) HDAC1SMN1; SMN2NPC1RAB9ACASP3
SCHEMBL4078006 0.85 SMN1; SMN2 (0.60) HDAC1SMN1; SMN2NPC1RAB9APOLB
SCHEMBL15598651 0.84 SMN1; SMN2 (0.69) HDAC1SMN1; SMN2NPC1RAB9ACASP3
SCHEMBL9821067 0.83 POLB (0.69) HDAC1SMN1; SMN2NPC1RAB9ACASP3
SCHEMBL17244480 0.83 HDAC1 (0.58) HDAC1SMN1; SMN2NPC1RAB9ACASP3
SCHEMBL863069 0.82 RAB9A (0.58) HDAC1SMN1; SMN2NPC1RAB9APOLB
SCHEMBL30368269 0.82 RAB9A (0.58) HDAC1SMN1; SMN2NPC1RAB9APOLB
SCHEMBL9821015 0.82 ALDH1A1 (0.48) HDAC1SMN1; SMN2NPC1RAB9AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110668948-B Preparation method of 4-chloro-2-fluoro-5-nitroacetophenone 苏州敬业医药化工有限公司 2022-03-08 CN claimed
CN-110668948-A Preparation method of 4-chloro-2-fluoro-5-nitroacetophenone 苏州敬业医药化工有限公司 2020-01-10 CN claimed
CN-110668948-B Preparation method of 4-chloro-2-fluoro-5-nitroacetophenone 苏州敬业医药化工有限公司 2022-03-08 CN disclosed
CN-111072513-B Preparation method of hepatitis drug intermediate 苏州敬业医药化工有限公司 2022-03-08 CN disclosed
CN-111072513-A Preparation method of hepatitis drug intermediate 苏州敬业医药化工有限公司 2020-04-28 CN disclosed
CN-110668948-A Preparation method of 4-chloro-2-fluoro-5-nitroacetophenone 苏州敬业医药化工有限公司 2020-01-10 CN disclosed
US-7786155-B2 Organic compounds NOVARTIS AG (CH) 2010-08-31 US disclosed
EP-2212314-A1 IMIDAZOLIDINE-2,4-DIONE (HYDANTOIN) DERIVATIVES USEFUL AS NPY Y2 RECEPTOR MODULATORS Novartis AG (CH) 2010-08-04 EP disclosed
EP-2212295-A2 4-PHENYL-5-OXO-IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEROF Novartis AG (CH) 2010-08-04 EP disclosed
WO-2009050201-A2 4-PHENYL-5-OXO-IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEROF NOVARTIS AG (CH) 2009-04-23 WO disclosed
WO-2009050200-A1 IMIDAZOLIDINE-2,4-DIONE (HYDANTOIN) DERIVATIVES USEFUL AS NPY Y2 RECEPTOR MODULATORS NOVARTIS AG (CH) 2009-04-23 WO disclosed
US-20090099243-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-04-16 US disclosed
US-20090099244-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-04-16 US disclosed
EP-0224001-B1 ANTHRANILONITRILE DERIVATIVES AND RELATED COMPOUNDS AS USEFUL AGENTS FOR PROMOTING GROWTH, IMPROVING FEED EFFICIENCY, AND FOR INCREASING THE LEAN MEAT TO FAT RATIO OF WARM-BLOODED ANIMALS AMERICAN CYANAMID COMPANY (US) 1991-03-20 EP disclosed
US-4863959-A Anthranilonitrile derivatives as useful agents for promoting growth, improving feed efficiency, and for increasing the lean meat to fat ratio of warm-blooded animals AMERICAN CYANAMID COMPANY (US) 1989-09-05 US disclosed
EP-0224001-A1 Anthranilonitrile derivatives and related compounds as useful agents for promoting growth, improving feed efficiency, and for increasing the lean meat to fat ratio of warm-blooded animals AMERICAN CYANAMID COMPANY (US) 1987-06-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099244-A1 ORGANIC COMPOUNDS SLCO4C1, SLC10A6, SLCO1B1 HDAC1 671/4885SMN1; SMN2 4082/4885NPC1 464/4885
US-20090099243-A1 ORGANIC COMPOUNDS SLCO4C1, SLCO1B1, SLCO1B3 HDAC1 750/4885SMN1; SMN2 3920/4885NPC1 392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.